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Children with congenital heart disease (CHD) are at risk for increased morbidity from viral lower respiratory tract infections
because of anatomical cardiac lesions than can worsen an already compromised respiratory status. Respiratory syncytial virus
(RSV) remains an important pathogen in contributing toward the morbidity in this population. Although the acute treatment of
RSV largely remains supportive, the development of monoclonal antibodies, such as palivuzumab, has reduced the RSV-related
hospitalization rate in children with CHD. This review highlights the speciﬁc cardiac complications of RSV infection, the acute
treatment of bronchiolitis in patients with CHD, and the search for new therapies against RSV, including an eﬀective vaccine,
because of the high cost associated with immunoprophylaxis and its lack of reducing RSV-related mortality.
1.Introduction
Surgical outcomes in children with congenital heart disease
(CHD) have improved over the past two decades because
of advances in prenatal diagnosis, surgical and cardiopul-
monary bypass techniques, and postoperative management
[1]. In fact, it is expected that adult patients with CHD
now exceed the number of children with CHD [2], and the
majority of patients who have undergone surgical correction
for their CHD do not consider their quality of life to be
impacted by their malformation [3].
Theseimprovedoutcomesrequireasigniﬁcanteconomic
investment so that processes of care are optimally aligned
throughout the continuum of a patient’s life from initial
diagnosis, through his or her surgical correction (including
postoperative management)andafterhospitalizationfollow-
up. However, a signiﬁcant number of these children will
require multiple surgeries before they are fully corrected and,
therefore, can be exposed to community-acquired respira-
tory infections which can result in substantial morbidity
and mortality. Outside the perioperative period, respiratory
infections are signiﬁcantly more likely to be the cause of
death during the winter than the summer [4]. Consequently,
it is critical for both primary care physicians and pediatric
cardiologists to remain familiar with the current epidemi-
ology and clinical management of respiratory pathogens in
children with CHD, while also understanding what contem-
porary prophylactic options exist in minimizing the burden
of viral respiratory infections throughout this population.
Over one-half of hospital admissions related to acute
respiratory tract infections in children with CHD are due to
bronchiolitis [5]. In the United States, the number of out-
patient visits and the number and percentage of yearly hos-
pitalizations for bronchiolitis have actually increased since
1980 [6, 7]. Respiratory syncytial virus (RSV) remains the
most common etiologic agent of bronchiolitis and is respon-
sible for up to 90% of hospitalizations due to bronchiolitis
[8]. Children with CHD have higher rates of hospitalization,
a longer length of stay, and risk of death if they become
infected with RSV compared to children without CHD
[9–11].
It is estimated that there are 33.8 million episodes of
RSVlowerrespiratorytractinfection(LRTI)worldwide,with
children in developing countries twice as likely to be infected2 International Journal of Pediatrics
as compared to children in industrial countries. Approxi-
mately 10% of these episodes will lead to hospitalization,
anditisestimatedthat66,000–199,000childrenwilldiefrom
RSV-associated LRTI; 99% of whom will be from developing
countries [12].
2. Respiratory SyncytialVirus
RSV is an enveloped RNA virus whose genome encodes
several structural proteins including the (G) protein, which
promotes viralattachment,and the fusion(F)protein, which
promotespenetration.Therearetwogroups,AandB,ofRSV
strains that circulate together during yearly outbreaks [8].
2.1.ClinicalSymptomsandDiagnosis. Typicallypatientshave
rhinorrhea and a low-grade fever that can progress to cough
andrespiratorydistressoverthenextfewdaysandcanimpair
feeding and sleeping. Infants <3 months of age can also
present with apnea [13]. Patients typically will have crackles
and/or wheezes on lung exam and depending on the severity
of infection, tachypnea, chest wall retractions, and hypoxia.
The diagnosis is typically made clinically based on the above
ﬁndings,althoughviralculture,directﬂuorescentassays,and
rapid antigen detection can be used. Also, the development
of real-time polymerase chain reaction (RT-PCR) testing has
allowed more rapid detection of respiratory pathogens in the
setting of pediatric respiratory infections.
2.2. The Impact of Viral Respiratory Infections on CHD.
Cabalka [14] highlighted the physiologic risk factors in
children with CHD that can contribute to worse clinical out-
comes from viral respiratory infections. Children who have
left-to-right shunt lesions may have increased pulmonary
blood ﬂow that leads to pulmonary edema and decreased
functional residual capacity. These alterations in pulmonary
mechanics further lead to areas of atelectasis and ventilation-
perfusion mismatch, ultimately leading to hypoxia. Patients
with cyanotic congenital heart disease may experience inten-
siﬁcation in their baseline level of cyanosis due to bron-
chiolitis-related reductions in lung volume and airway
diameter superimposed on their already reduced pulmonary
blood ﬂow and obligatory right-to-left shunt. Children with
CHD may also have impaired ventricular function leading
to higher pulmonary venous pressures, capillary leak, and
pulmonary edema which further contribute to increased
ventilation-perfusion mismatch.
Although earlier reports indicated mortality rates of 37%
for RSV-infected CHD patients and 73% in patients with
pulmonary hypertension [15], more recent studies suggest
that mortality rates have decreased to <2%, even in children
with pulmonary hypertension [16]. Improvements in critical
care medicine have led to the decrease in mortality rates
but screening for RSV prior to surgical intervention also has
contributed to a reduction in RSV-related pulmonary hyper-
tension and therefore a reduction in postoperative morbidity
[17, 18]. Risk factors for RSV hospitalization in children
with heart disease include trisomy-21, cardiomyopathy, and
hemodynamicallysigniﬁcantheartdisease.Youngerpatients,
Table 1: Cardiovascular complications associated with RSV infec-
tion.
Sinoatrial block
Tachyarrhythmias
Atrioventricular block
Pericarditis
Myocarditis
Complete heart block
Reduced right ventricular function
particularly those with heart failure, can be expected to have
a more severe clinical course [19].
Other viruses other than RSV are responsible for bron-
chiolitis. The development of molecular testing for viruses
obtained from nasopharyngeal swabs or aspirates via RT-
PCR has highlighted the role of dual infections in patients
with viral respiratory tract infections. However, the role
of dual infection correlating to increased clinical severity
is unclear. Although some investigators have reported no
clinical diﬀerences in patients with dual infections [20–22],
others have reported more severe bronchiolitis in patients
who have had multiple viruses detected [23–26]. In the stud-
ies that demonstrated a more severe clinical infection with
dual respiratory pathogens, two studies speciﬁcally excluded
children with CHD [23, 25] while the other two studies
enrolled children with CHD but did not separately report
clinical outcomes in this group [24, 26]. Richard et al. [26],
however, did include children with CHD as part of a cohort
of children with underlying chronic illness and reported that
dual infection with RSV and rhinovirus was signiﬁcantly
associated with admission to the Pediatric Intensive Care
Unit. There is also no evidence that the availability to di-
agnose dual pathogens via RT-PCR testing leads to shorter
hospital stays or reduces antibiotic use in children with acute
respiratory infection [27].
There are diﬀe r e n tr i s kf a c t o r sb e t w e e nR S Va n dn o n -
RSV bronchiolitis. In one study, children hospitalized with
RSV bronchiolitis were younger and had less previously
known risk factors for RSV such as prematurity, chronic
lung disease, and congenital heart disease; this ﬁnding may
reﬂect the beneﬁt of immunoprophylaxis against RSV. In
fact, the adoption of anti-RSV prophylaxis may explain
why non-RSV bronchiolitis may now be more prevalent
in hospitalized children with CHD and other high-risk
conditions than RSV bronchiolitis [17, 28]. Disease severity
was greater in children with RSV bronchiolitis versus non-
RSV bronchiolitis as measured by signiﬁcant diﬀerences in
length of hospitalization stay, length of stay in the PICU,
intubation duration, and percentage of children requiring
supplemental oxygen [7].
2.3. Cardiac Complications of RSV. Although perhaps not as
well appreciated as the pulmonary manifestations of RSV
infection, the virus can lead to cardiac complications in
hospitalized children [29]. Table 1 lists the cardiovascular
complications that have been associated with RSV infection.International Journal of Pediatrics 3
Table 2: Evidence-based treatment options for bronchiolitis.
Outpatient Inpatient Intensive Care Unit Not eﬀective
Nebulized Epinephrine
Nebulized No speciﬁc recommendations Bronchodilators
Hypertonic Consider empiric antibiotics for infants with
respiratory failure Glucocorticoids
Saline (3%)
Source: Bialy et al. [32]a n dL e v i ne ta l .[ 33].
In a study of otherwise healthy 69 children hospitalized with
bronchiolitis in Italy, none of whom required admission to
the intensive care unit or treatment with bronchodilators,
sinoatrial blocks were signiﬁcantly more likely to occur in
RSV-positive patients than in RSV-negative patients. Fortu-
nately, these sinoatrial blocks were always asymptomatic and
24-hour Holter ECG monitoring demonstrated complete
regression of the sinoatrial blocks at 28 ± 3d a y s . T h i s
suggests that direct cardiac involvement can occur from RSV
infection rather than secondary to lung alterations alone
[30]. A study of 34 mechanically ventilated children with
RSV bronchiolitis who did not have CHD reported that 20%
hadreducedrightventricularfunctionandcardiactroponins
were elevated in 41%. However, in this same study, there was
no evidence of left ventricular dysfunction nor was there any
relationship to elevations in myocardial or hepatic levels of
troponin or transaminases, respectively, making it diﬃcult
to speciﬁcally attribute RSV as the cause of cardiac ﬁndings
[31].
2.4. Treatment of Bronchiolitis. Historically the treatment
of bronchiolitis has been supportive. Maintaining adequate
oxygen saturation and preventing dehydration has been the
mainstay of treatment for several decades. An overview of
bronchiolitis treatment in various clinical settings can be
foundinTable 2.Inoutpatientswithbronchiolitis,nebulized
epinephrine reduced the likelihood of hospitalization and
improved clinical severity scores at 60 and 120 minutes
after treatment when compared to placebo. In the inpatient
setting, the only intervention that has been shown to lead
to clinically meaningful outcomes such as a reduction in
length of stay was nebulized hypertonic saline (3%). Chest
physiotherapy demonstrates some improvement in clinical
score at 1–3 days but the evidence of beneﬁt is weak.
Although there is not a recommended strategy for patients
in an ICU setting, surfactant and immunoglobulin therapies
along with standardized ventilation protocols may hold
promise in the future [32]. It should be emphasized that
the successful treatment options presented in Table 2 have
excluded children with CHD, so caution is warranted when
attempting to form more generalized conclusions regarding
the eﬀectiveness of these therapeutic options. Rates of
bacterial pneumonia can be 20% or higher in patients with
RSV infection and respiratory failure. Therefore it appears
reasonable to start empiric antibiotics for 24 to 48 hours
pending culture results in this group of patients [33].
A common clinical scenario that health care providers
face is how to evaluate and treat the presence of fever in
infants with bronchiolitis, particularly those under the age of
three months. Fortunately, the overall frequency of serious
bacterial infections (SBIs) in a study of over 4000 patients
<2 years of old, hospitalized with bronchiolitis, was low.
The overall frequency of SBIs was 1.0% in RSV-positive
patients and 0.7% in RSV-negative patients (not statistically
signiﬁcant). The most common SBI was a urinary tract in-
fection, and there were no cases of positive cerebrospinal
ﬂuid cultures [7].
Currently, respiratory support interventions for patients
with severe bronchiolitis are being examined to reduce the
need for mechanical ventilation but the choice of modalities
is still largely based on clinical judgment and larger clinical
trials are needed to deﬁne optimal strategies. In this regard, a
recent retrospective study that examined heated, humidiﬁed,
high-ﬂow nasal cannula (HFNC) demonstrated a signiﬁcant
68% reduction in the need for intubation in infants with
bronchiolitis. HFNC allows the delivery of high inspired gas
ﬂows, with or without an increased oxygen concentration,
and provides a variable degree of continuous positive airway
pressure that leads to decreased work of breathing. However,
prospective randomized trials are needed [34].
3.Immunoprophylaxis
3.1. Palivizumab. Palivizumab is a humanized murine mon-
oclonal antibody directed against the fusion protein of
RSV that in preclinical trials was able to neutralize both
subtypes of RSV strains and was 50- to 100-fold more
potent than respiratory syncytial virus immune globulin
administered intravenously (RSV-IGIV) [35]. The use of
RSV-IVIG, containing high levels of RSV-neutralizing anti-
body, became contraindicated in the use of children with
cyanotic CHD due to an increased frequency of cyanotic
events. This increase in frequency of cyanotic episodes may
relate to increased blood viscosity, secondary to reactive
polycythemia, commonly seen in patients with a right-to-left
cardiac shunt [36].
In a multinational, randomized, double-blind, placebo-
controlled trial, children ≤24 months of age who had
hemodynamically signiﬁcant congenital heart disease were
administered either 15mg/kg of palivizumab or an iden-
tically appearing placebo every 30 days for a total of 5
doses during four consecutive RSV seasons (1998–2002). Pa-
livizumab recipients experienced a signiﬁcant 45% rela-
tive reduction in RSV hospitalizations when compared to
placebo (9.7% hospitalization rate in placebo group vs.
5.3% in palivizumab group). Palivizumab recipients also
spent signiﬁcantly less days in the hospital and had less
days requiring oxygen supplementation. There was also
a trend for decreased need of intensive care and mechanical
ventilation. The mortality rate was 3.3% in palivizumab4 International Journal of Pediatrics
Table 3: Palivizumab prophylaxis in children with CHD and its impact on RSV hospitalization rate.
Author (reference) Location Methodology
Hospitalization
rate without
prophylaxis
Hospitalization
rate with
prophylaxis
Relative reduction
Feltes et al. [9] International
Randomized,
double-blind,
placebo-controlled
9.7% 5.3% 45.4%∗
Cohen et al. [37]U S A Prospective,
observational N/A 1.9% N/A
Chang and Chen [38] California, USA Observational 0.56% 0.46% 17.9%
Saji et al. [39] Japan Questionnaire N/A 4.6% N/A
Saji et al. [40] Japan Questionnaire 4.42% 2.53% 42.8%
∗Denotes statistical signiﬁcance.
recipients and 4.2% in placebo recipients but this did not
reach statistical signiﬁcance. An important clinical ﬁnding
in this trial was that palivizumab serum concentrations were
reduced 58% after cardiopulmonary bypass and therefore
led to the recommendation that another 15mg/kg dose
of palivizumab should be administered after surgery [9].
Table 3 highlightsstudiesthathavereportedontheimpactof
palivizumab prophylaxis in preventing RSV hospitalization
rate in children with CHD.
Table 4 highlights recommendations from the American
Academy of Pediatrics for palivizumab administration in
children with CHD. Adherence to the prophylaxis schedule is
critical since children with CHD who receive adequate RSV
prophylaxis are less likely to be hospitalized with an RSV
infection. L´ opez et al. reported that children who received
adequateRSVprophylaxiswere58%lesslikelytobehospital-
izedthanthosethatdidnothaveadequateprophylaxis(3.3%
vs. 7.9%) [5].
Children do not necessarily need to receive their ﬁrst
dose of palivizumab prophylaxis in the hospital setting but
can reliably receive it in an oﬃce-based or home-based
setting [42]. A recent systematic review of compliance with
palivizumab prophylaxis reported that home-based pro-
grams are associated with improved compliance compared
to oﬃce-based administration [43].
3.2. Motavizumab. Motavizumab was developed by aﬃnity
maturation of palivizumab, binds to the RSV fusion protein
70-fold better than palivizumab, and reduces pulmonary
RSV titers up to 100-fold lower compared to palivizumab in
cotton rats [44].
A multinational Phase 2 randomized, double-blind,
palivizumab-controlled study of children ≤24 months en-
rolled 1236 patients with hemodynamically signiﬁcant CHD,
or acyanotic CHD with pulmonary hypertension and/or
use of daily medication for congestive heart failure. The
safety proﬁles of motavizumab and palivizumab were similar
except motavizumab recipients had a signiﬁcantly higher
incidents of skin events such as cutaneous hypersensitivity
(1.6% vs. 0.3%, resp.; P = 0.038).
Although the study was not suﬃciently powered to com-
pare eﬃcacy between the two drugs, there was a nonsignif-
icant diﬀerence in RSV-related hospitalizations between
motavizumab and palivizumab (1.9% vs. 2.6%, resp.). There
was no signiﬁcant diﬀerence between groups related to
percentage of hospitalized patients requiring supplemental
oxygen, number of intensive care unit admissions, need
for mechanical ventilation, and the length of hospital stay.
Therewasalsonosigniﬁcantdiﬀerenceinmedicallyattended
lower respiratory tract infections between motavizumab and
palivizumab (1.0% vs. 1.9%, resp.). Mortality rates were also
similar between motavizumab and palivizumab recipients
(1.5%vs.1.6%, resp.) [45].BecauseRSV replication depends
on an RNA polymerase that can have a high mutation
rate, there has been concern that immunoprophylaxis may
increase the potential of resistant RSV mutants. Although
resistantRSVvariantsweredetectedin ∼5%ofbreakthrough
cases, these did not appear to worsen the patient’s clinical
outcome [46].
In patients who underwent cardiopulmonary bypass
surgery, those who received an extra dose of motavizumab
achieved a similar serum trough concentrations as those
who did not undergo cardiopulmonary bypass, highlighting
the need to redose motavizumab after cardiopulmonary
bypass surgery. However, because of motavizumab’s lack of
improved eﬃcacy over palivizumab and higher number of
allergic reactions, it was not approved by the United States
Food and Drug Administration and is not available for
immunoprophylaxis against RSV.
3.3. Economic Considerations of Immunoprophylaxis. Al-
though immunoprophylaxis has been showed to reduce
hospital admissions related to RSV, there has not been evi-
dence that mortality has improved. As a result, controversy
regarding the cost-beneﬁt of administering palivizumab to
all children <24 months of age with hemodynamically
signiﬁcant congenital heart disease has been raised [47],
especially since the RSV hospitalization rate in children with
CHD is lower in children >12 months of age [5, 19, 48].
Cost-eﬀectivenessstudiesofpalivizumabvarygreatlyintheir
methodology leading to disparate conclusions regarding
their eﬀectiveness. The cost-beneﬁt of immunoprophylaxis
is inﬂuenced by the rate of RSV hospitalization so that
immunoprophylaxis given to an infant in the Canadian
Inuit region, which has the highest rate of RSV infectionInternational Journal of Pediatrics 5
Table 4: Recommendations for palivizumab prophylaxis in children with CHD.
(i) ≤24 months of age with hemodynamically signiﬁcant cyanotic CHD
(a) Infants receiving medication to control congestive heart failure
(b) Infants with moderate-to-sever pulmonary hypertension
(c) Infants with cyanotic heart disease
(ii) Initiate 15mg/kg of palivizumab prophylaxis monthly during RSV season (typically November through March in North America)
(iii) Give additional dose of palivizumab 15mg/kg in patients who require cardiopulmonary bypass for a surgical procedure and will
continue to need prophylaxis as soon as they are medically stable
Source: [41].
globally, would lead to a diﬀerent conclusion regarding cost-
eﬀectiveness than an infant where the RSV hospitalization
rateislowersuchasinFlorida[49,50].Inaddition,howcosts
are assigned in economic modeling may have an impact on
the cost-eﬀectiveness of palivizumab since lost productivity
and the assumption that palivizumab can reduce health-
care resource utilization for recurrent wheezing have been
included in some analyses [51].
Although pediatric cardiologists from Europe have
published similar recommendations as the AAP regarding
indicationsforpalivizumabprophylaxis[52],othercountries
liketheUKandSwitzerlandhaveadoptedamorestrictpolicy
regarding palivizumab and recommend its administration
only to infants less than six months of age who have left-
to-right shunt hemodynamically signiﬁcant congenital heart
disease and/or pulmonary hypertension (UK), or who are
<12 months of age and have additional risk factors like
cyanotic CHD, pulmonary hypertension, or congestive heart
failure (Switzerland) [53].
There has been robust discussion as to whether infection
with RSV or other viruses in infancy can lead to the
development of asthma since previous studies have reported
that persistent respiratory symptoms and impaired lung
function can occur until later childhood and even young
adulthood[54,55].Whetherviralrespiratorytractinfections
are causal factors of asthma or merely are coincidental in a
child predisposed to asthma is still unresolved [56]. Recently,
a multicenter trial in Europe and Canada demonstrated that
palivizumab administration given in the ﬁrst year of life
to premature infants signiﬁcantly decreased the likelihood
of recurrent wheezing in children up to 5 years of age but
did not have any eﬀect on infants who had family history
of atopy, suggesting that the cause of wheezing is diﬀerent
between asthma and RSV [57].
The debate about the cost-eﬀectiveness about palivi-
zumab only serves to highlight the need for more eﬀective
prevention strategies for such a prominent illness that
contributes signiﬁcantly to worldwide childhood morbidity
and mortality.
4. FutureDirections
Previous attempts at developing a vaccine to prevent RSV
infection have been unsuccessful due to several factors such
as the early age of infection, the ability of the virus to evade
preexisting immune responses, a failure of natural infection
to confer immunity throughout an individual’s life, a legacy
of vaccine-enhanced disease, and animal models that do not
precisely mimic human RSV [58]. In the 1960s, recipients
of a formalin-inactivated vaccine experienced increased
morbidity and mortality upon subsequent exposure to RSV
[59, 60].
Since this time, subunit vaccines that target the F and
G proteins of RSV, the delivery of vaccine antigens by live
viral vectors such as recombinant attenuated parainﬂuenza
virus type-3 expressing RSV-F protein, and live-attenuated
vaccines have undergone testing in preclinical trials and
Phase I trials and may hold promise as future vaccine
candidates against RSV [58, 61, 62]. Inducing neutralizing
antibody to reduce antigen accumulation and inducing
CD8+ T cells to clear RSV-infected cells are thought to
be important principles for RSV vaccine development [58].
However, even if a vaccine emerges, it is likely that multiple
doses will be needed at frequent intervals so that adequate
immunity against RSV develops. This may complicate eﬀorts
to achieve the full beneﬁts of vaccination in low-income
countrieswheretheburdenofRSVisgreatest.Additionally,a
smallinterferingRNA(siRNA)thatimpactsRSVreplication,
including RNA polymerase function, was delivered via nasal
spray to 88 subjects before and after they were given an
inoculum of wild-type RSV and signiﬁcant antiviral activity
with favorable safety proﬁle was demonstrated supporting
further investigation of this approach as a treatment for
RSV infection [63]. This research may also lead to the
development of other locally delivered siRNAs against other
respiratory pathogens.
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